Preoperative radiotherapy and concomitant capecitabine treatment induce thymidylate synthase and thymidine phosphorylase mRNAs in rectal carcinoma

Neoplasma

Volumn 54, Issue 5, 2007, Pages 447-453

  Kocakova, I ^a   Svoboda, M ^a   Kubosova, K ^a   Chrenko, V ^a   Roubalova, E ^a   Krejci, E ^a   Sefr, R ^a   Slampa, P ^a   Frgala, T ^a   Zaloudik, J ^a  

^a NONE

Author keywords

Capecitabine; Preoperative chemoradiotherapy; Rectal Cancer; Thymidine phosphorylase induction; Thymidylate synthase

Indexed keywords

CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; FLUOROURACIL; MESSENGER RNA; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER REGRESSION; CANCER STAGING; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; ENZYME INDUCTION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MORNING DOSAGE; PREOPERATIVE RADIOTHERAPY; PROGNOSIS; RADIATION DOSE; RECTUM CARCINOMA; RECTUM RESECTION; RECURRENCE RISK; TREATMENT RESPONSE; TUMOR BIOPSY; BLOOD; GENETIC MARKER; GENETICS; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; POLYMERASE CHAIN REACTION; RECTUM TUMOR;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOEMBRYONIC ANTIGEN; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; FLUOROURACIL; GENETIC MARKERS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PYRIMIDINES; RECTAL NEOPLASMS; RNA, MESSENGER; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE;

EID: 35448929086     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. WALKO CM, LINDLEY C. Capecitabine: a review. Clin Ther 2005; 27: 23-44.
2. McGINN CJ, LAWRENCE TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 2001; 11: 270-280 (Pubitemid 32959662)
3. BEN-JOSEF E, SHIELDS AF, VAISHAMPAYAN U et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 59: 454-459 (Pubitemid 38622600)
4. NGAN SY, MICHAEL M, MACKAY J et al. A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. Br J Cancer 2004; 91: 1019-1024 (Pubitemid 39336237)
5. RODEL C, GRABENBAUER GG, PAPADOPOULOS T et al. Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003; 21: 3098-3104 (Pubitemid 46613485)
6. KIM JC, KIM TW, KIM JH et al. Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2005; 63: 346-353 (Pubitemid 41317150)
7. ISHIKAWA T, UTOH M, SAWADA N et al. Tumor selective delivery of 5-fluorouracil by capecitabine, a new oral fluoropyrimidine carbamate, in human cancer xenografts. Biochem Pharmacol 1998; 55: 1091-1097
8. HOTTA T, TANIGUCHI K, KOBAYASHI Y et al. Increased expression of thymidine phosphorylase in tumor tissue in proportion to TP-expression in primary normal tissue. Oncol Rep 2004; 12: 539-541
9. KAMOSHIDA S, SHIOGAMA K, SHIMOMURA R et al. Immunohistochemical demonstration of fluoropyrimidinemetabolizing enzymes in various types of cancer. Oncol Rep 2005;14: 1223-1230
10. ELIASON JF, MEGYERI A. Potential for predicting toxicity and response of fluoropyrimidines in patients. Curr Drug Targets 2004; 5: 383-388 (Pubitemid 38559348)
11. LASSMANN S, HENNIG M, ROSENBERG R et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis. 2005; Aug 13: [Epub ahead of print]
12. LI H, SUO Z, ZHANG Y et al. The prognostic significance of thymidine phosphorylase, thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expressions in breast carcinomas. Histol Histopathol 2004; 19: 129-136
13. STEPANOVA EV, BOKHIAN BIU, PETROVICHEV NN et al. Thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in soft-tissue sarcoma versus capecitabine potential. Vopr Onkol 2005; 51: 314-316 (Pubitemid 43079899)
14. SAIF MW, ELOUBEIDI MA, RUSSO S et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol 2005; 23: 8679-8687
15. SALONGA D, DANENBERG KD, JOHNSON M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.
16. LENZ HJ, HAYASHI K, SALONGA D et al. P53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998; 4: 1243-1250
17. METZGER R, DANENBERG K, LEICHMAN CG et al. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin Cancer Res 1998; 4: 2371-2376
18. Grem JL, Steinberg SM, Chen AP et al. The utility of monitoring carcinoembyronic antigen during systemic therapy for advanced colorectal cancer. Oncol Rep 1998; 5: 559-567
19. RAPELLINO M, PIANTINO P, PECCHIO F et al. Disappearance curves of tumor markers after radical surgery. Int J Biol Markers 1994; 9: 33-37
20. OKEN MM, CREECH RH, TORMEY DC et al. Toxicity And Response Criteria Of The Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
21. L.H. SOBIN, CH. WITTEKIND (ed): TNM Classification of Malignant Tumours (ed 6). New Jersey: John Wiley & Sons, 2002.
22. FAERDEN AE, NAIMY N, WIIK P et al. Total Mesorectal Excision for Rectal Cancer: Difference in Outcome for Low and High Rectal Cancer. Dis Colon Rectum. 2005; Oct 3: [Epub ahead of print].
23. MANDARD AM, DALIBARD F, MANDARD JC et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 1994; 73: 2680-2686
24. BOUZOURENE H, BOSMAN FT, SEELENTAG W et al. Importance of tumor regression assessment in predicting the outcome in patients with locally advanced rectal carcinoma who are treated with preoperative radiotherapy. Cancer 2002; 94: 1121-1130
25. WANG WS, LIN JK, LIN TC et al. EIA versus RIA in detecting carcinoembryonic antigen level of patients with metastatic colorectal cancer. Hepatogastroenterology 2004; 51: 136-141
26. SAMBROOK J, RUSSELL D. Molecular Cloning: A Laboratory Manual (ed 3). Cold Spring Harbor NY: CSHL Press, 2001.
27. The Basic Local Alignment Search Tool (BLAST). http:// www.ncbi.nlm.nih.gov/BLAST/.
28. StatSoft Inc., Tulsa, USA.
29. DOUGLAS G. ALTMAN. Practical Statistics for Medical Research. CRC Press, 1991: 139-288.
30. JAKOB C, AUST DE, MEYER W et al. Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer. J Pathol 2004; 204: 562-568
31. KORNMANN M, LINK KH, GALUBA I et al. Association of time to recurrence with thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression in stage II and III colorectal cancer. J Gastrointest Surg 2002; 6: 331-337
32. JAKOB C, LIERSCH T, MEYER W et al. Prognostic value of histologic tumor regression, thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase in rectal cancer UICC Stage II/III after neoadjuvant chemoradiotherapy. Am J Surg Pathol 2006; 30: 1169-74. Erratum in: Am J Surg Pathol 2006; 30:1489.
33. ISHIBIKI Y, KITAJIMA M, SAKAMOTO K et al. Intratumoural thymidylate synthase and dihydropyrimidine dehydrogenase activities are good predictors of 5-fluorouracil sensitivity in colorectal cancer. J Int Med Res 2003; 31: 181-187 (Pubitemid 36805814)
34. KORNMANN M, SCHWABE W, SANDER S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003; 9: 4116-4124
35. WESTRA JL, HOLLEMA H, SCHAAPVELD M et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005; 16: 1646-1653
36. UCHIDA K, HAYASHI K, KURAMOCHI H et al. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int J Oncol 2001; 19: 341-346
37. PETERS GJ, BACKUS HH, FREEMANTLE S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
38. SAWADA N, ISHIKAWA T, SEKIGUCHI F et al. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human cancer xenografts. Clin Cancer Res 1999; 5: 2948-2953
39. KOBAYASHI M, OKAMOTO K, AKIMORI T et al. Localization of thymidine phosphorylase in advanced gastric and colorectal cancer. J Mol Histol 2004; 35: 69-74. (Pubitemid 40585336)
40. OGAWA M, IKEUCHI K, TAKAO Y et al. The activities of thymidine phosphorylase and dihydropyrimidine dehydrogenase in colorectal cancer depend on where the sample is taken. Oncol Rep 2005; 14: 331-335
41. NAKAGAWA T, OTAKE Y, YANAGIHARA K et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer 2004; 43: 145-149 (Pubitemid 38114742)
42. ACKLAND SP, PETERS GJ. Thymidine phosphorylase: its role in sensitivity and resistance to anticancer drugs. Drug Resist Updat 1999; 2: 205-214.
43. FURUKAWA T, YOSHIMURA A, SUMIZAWA T et al. Angiogenic factor. Nature 1992; 356: 668.
44. WALTENBERGER J, USUKI K, FELLSTROM B et al. Platelet-derived endothelial cell growth factor. Pharmacokinetics, organ distribution and degradation after intravenous administration in rats. FEBS Lett 1992; 313: 129-132
45. CICCOLINI J, EVRARD A, CUQ P. Thymidine phosphorylase and fluoropyrimidines efficacy: a Jekyll and Hyde story. Curr Med Chem Anticancer Agents 2004; 4: 71-81. Review.
46. NOZAWA T, ENOMOTO T, KOSHIDA Y et al. Specific enhanced expression of platelet-derived endothelial cell growth factor in submucosa of human colorectal cancer. Dis Colon Rectum 2004; 47: 2093-2100 (Pubitemid 40179072)
47. GYORFFY B, SUROWIAK P, KIESSLICH O et al. Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 2006; 118: 1699-1712
48. SCHMIDT WM, KALIPCIYAN M, DORNSTAUDER E et al. Dissecting progressive stages of 5-fluorouracil resistance in vitro using RNA expression profiling. Int J Cancer 2004; 112: 200-212.
49. AYERS M, SYMMANS WF, STEC J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 2004; 22: 2284-2293 (Pubitemid 41115384)
50. LI Y, HUSSAIN M, SARKAR SH et al. Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells. BMC Cancer 2005; 5: 7.
51. INOUE Y, SHIRANE M, MIKI C et al. Gene expression profiles of colorectal carcinoma in response to neo-adjuvant chemotherapy. Int J Oncol 2004; 25: 1641-1649